Yunho Jin

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 6.0

ph-index = 4

Forward Citations = 42(Granted Patents)

Company Filing History:

Years Active: 2013-2024

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12171839 - Antibody drug conjugates for ablating hematopoietic stem cells (2024-12-24),

2. 11357864 - Antibody drug conjugates for ablating hematopoietic stem cells (2022-06-14),

3. 10787480 - Cytotoxic peptides and conjugates thereof (2020-09-29),

4. 10604547 - Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase (2020-03-31),

5. 10464969 - Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase (2019-11-05),

6. 10392421 - Cytotoxic peptides and conjugates thereof (2019-08-27),

7. 9988420 - Cytotoxic peptides and conjugates thereof (2018-06-05),

8. 9938323 - Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase (2018-04-10),

9. 8957081 - Compounds and compositions as protein kinase inhibitors (2015-02-17),

10. 8546370 - Compounds and compositions as kinase inhibitors (2013-10-01),

11. 8399450 - Compounds and compositions as protein kinase inhibitors (2013-03-19),

12. 8372858 - Compounds and compositions as protein kinase inhibitors (2013-02-12),

Title: Innovations of Yunho Jin in Antibody Drug Conjugates

Introduction

Yunho Jin is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of biotechnology. With a total of 12 patents to his name, he has made remarkable advancements in the development of antibody drug conjugates.

Latest Patents

One of Yunho Jin's latest patents focuses on antibody drug conjugates for ablating hematopoietic stem cells. This invention provides a method where an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The invention also includes pharmaceutical compositions comprising these antibody drug conjugates, along with methods for making and using such compositions in patients requiring hematopoietic stem cell ablation.

Career Highlights

Throughout his career, Yunho Jin has worked with notable companies such as Novartis AG and Irm LLC. His work in these organizations has allowed him to further his research and development in innovative therapeutic solutions.

Collaborations

Yunho Jin has collaborated with esteemed colleagues, including Tetsuo Uno and Bernhard Hubert Geierstanger. These partnerships have contributed to the advancement of his research and the successful development of his inventions.

Conclusion

Yunho Jin's work in the field of antibody drug conjugates showcases his dedication to innovation and improving patient outcomes. His contributions continue to influence the biotechnology landscape significantly.

This text is generated by artificial intelligence and may not be accurate.